| Sheline, Yvette I |
| Completed | 4 | 119 | US | Escitalopram + Celecoxib, Escitalopram + Placebo | University of Pennsylvania | Depression, Inflammation | 07/22 | 07/22 | | |
NCT03096886: Novel Neural Circuit Biomarkers of Major Depression Response to CCBT |
|
|
| Completed | N/A | 132 | US | Computer-Augmented Cognitive Behavioral Therapy, CCBT, Computer-Assisted Cognitive Behavioral Therapy | University of Pennsylvania | Depression, Major Depressive Disorder, Depressive Disorder, Depression, Unipolar | 10/23 | 10/23 | | |
| Recruiting | N/A | 40 | US | intermittent Theta Burst Stimulation | University of Pennsylvania | Treatment Resistant Depression | 05/25 | 07/25 | | |
| Completed | N/A | 34 | US | Intensive intermittent theta-burst stimulation (iTBS) | University of Pennsylvania | Bipolar Depression, Treatment Resistant Depression | 02/24 | 02/24 | | |
| Recruiting | N/A | 34 | US | Active Closed Loop Real Time fMRI Neurofeedback, Sham Closed Loop Real Time fMRI Neurofeedback | University of Pennsylvania | MDD | 05/25 | 11/25 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Guthery, Stephen |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia, Neonatal Cholestasis | 05/29 | 05/29 | | |
| Recruiting | N/A | 1265 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia | 05/29 | 05/29 | | |
| Suspended | N/A | 1675 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency | 05/29 | 05/29 | | |
| Suspended | N/A | 67 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan | Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation | 05/29 | 05/29 | | |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing | 05/29 | 05/29 | | |
| Lee, June Sung |
NCT04747613: Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria |
|
|
| Recruiting | 3 | 250 | Europe, Japan, US, RoW | Iptacopan, LNP023 | Novartis Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria | 10/27 | 10/27 | | |
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles |
|
|
| Recruiting | N/A | 30000 | Europe, Canada, US, RoW | MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint | Agendia | Breast Cancer | 04/37 | 12/37 | | |
| Drummond, Micah |
NCT03107884: Role of Metformin on Muscle Health of Older Adults |
|
|
| Active, not recruiting | 1 | 64 | US | Metformin (Bed Rest), Metformin hydrochloride, Fortamet, glucophage, Glumetza, Riomet, Placebo (Bed Rest), Metformin (2 week run-in only), Glucophage, Placebo (2 week run-in only) | University of Utah | Muscle Atrophy, Insulin Resistance | 11/25 | 11/25 | | |
| Recruiting | 1 | 50 | US | Metformin, Glucophage, Fortamet, Glumetza, Riomet, Placebo | University of Utah | Muscle Atrophy or Weakness | 05/29 | 05/30 | | |
NCT05392582: MicroRNA Regulation of Chronic Inflammation During Aging |
|
|
| Recruiting | N/A | 40 | US | | University of Utah | Chronic Inflammation | 01/27 | 01/28 | | |
| Recruiting | N/A | 45 | US | Limb immobilization, Muscle Disuse | University of Utah | Muscle Disuse | 04/27 | 04/28 | | |
| Christina, Melanie |
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain |
|
|
| Active, not recruiting | 2/3 | 602 | US, RoW | Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly | Paradigm Biopharmaceuticals USA (INC) | Osteoarthritis, Knee | 10/24 | 01/25 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
| Abraham, Josephine |
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension |
|
|
| Enrolling by invitation | 3 | 1400 | Europe, Canada, US, RoW | lorundrostat, Placebo | Mineralys Therapeutics Inc. | Hypertension | 12/25 | 12/26 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
| Feldman, Amy |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia, Neonatal Cholestasis | 05/29 | 05/29 | | |
| Recruiting | N/A | 1265 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia | 05/29 | 05/29 | | |
| Suspended | N/A | 1675 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency | 05/29 | 05/29 | | |
| Suspended | N/A | 67 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan | Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation | 05/29 | 05/29 | | |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing | 05/29 | 05/29 | | |
NCT04336735: Improving Immunization Rates in Transplant Candidates Through the Use of a Health Information Technology Tool |
|
|
| Recruiting | N/A | 45 | US | immunization app | University of Colorado, Denver, Agency for Healthcare Research and Quality (AHRQ) | Transplantation Infection, Vaccination | 08/24 | 08/24 | | |
| Jensen, Kyle |
NCT06553768: Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND) |
|
|
| Recruiting | 3 | 90 | Europe, Canada, US, RoW | Maralixibat, Formerly LUM001, SHP625, Placebo | Mirum Pharmaceuticals, Inc. | Cholestatic Liver Disease (except ALGS, PFIC, PBC and PSC) | 10/26 | 02/27 | | |
| Active, not recruiting | 3 | 254 | Europe, Canada, US, RoW | Odevixibat, Placebo | Albireo, an Ipsen Company | Biliary Atresia | 06/26 | 07/26 | | |
| Recruiting | 2 | 163 | US | High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago | Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation | 01/26 | 01/27 | | |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia, Neonatal Cholestasis | 05/29 | 05/29 | | |
| Recruiting | N/A | 1265 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia | 05/29 | 05/29 | | |
| Suspended | N/A | 1675 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency | 05/29 | 05/29 | | |
| Suspended | N/A | 67 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan | Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation | 05/29 | 05/29 | | |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing | 05/29 | 05/29 | | |
| Rutherford, Ann |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia, Neonatal Cholestasis | 05/29 | 05/29 | | |
| Recruiting | N/A | 1265 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia | 05/29 | 05/29 | | |
| Suspended | N/A | 1675 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency | 05/29 | 05/29 | | |
| Suspended | N/A | 67 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan | Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation | 05/29 | 05/29 | | |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing | 05/29 | 05/29 | | |
| Recruiting | N/A | 2230 | Canada, US | | Arbor Research Collaborative for Health | Liver Diseases | 05/29 | 05/29 | | |
| Mickey, Brian J |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US, RoW | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
| Active, not recruiting | 2/3 | 48 | US | Propofol, Diprivan | University of Utah | Treatment Resistant Depression | 12/22 | 07/24 | | |
NCT05301036: Personalized Ultrasonic Brain Stimulation for Depression |
|
|
| Active, not recruiting | 1/2 | 20 | US | Diadem prototype | University of Utah | Major Depressive Episode | 07/24 | 12/24 | | |
| Recruiting | N/A | 100 | US | Sham-stimulation, Active-stimulation | Abbott Medical Devices | Treatment Resistant Depression | 04/27 | 04/29 | | |
| Recruiting | N/A | 183 | US | Rumination-Focused CBT, Relaxation-based Therapy | Ohio State University, University of Exeter, National Institute of Mental Health (NIMH), University of Utah, Nationwide Children's Hospital, Utah Center for Evidence Based Treatment | Major Depressive Disorder, Mood Disorders | 04/25 | 03/26 | | |
| Carter, Jasmine |
| Recruiting | 3 | 198 | US | GIE Medical ProTractX3 TTS DCB, Control | GIE Medical | Esophageal Stricture | 07/25 | 12/29 | | |
NCT05556824: Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD |
|
|
| Recruiting | 2 | 156 | US | MHS-1031, Panosyl-isomaltooligosaccharide, Placebo | Microbiome Health Sciences, VBHRC Virginia Catalyst | Gastroesophageal Reflux | 04/25 | 04/25 | | |
| Matukewicz, Michelle |
COMAA, NCT05588739: Cognitive-Behavioral Therapy for Children With Nightmares as a Mediator of Suicide Risk |
|
|
| Completed | N/A | 58 | US | Cognitive Behavioral Therapy | University of Oklahoma, University of Tulsa | Nightmare | 06/23 | 06/23 | | |
NCT06033781: Cognitive-Behavioral Therapy for Children With Nightmares |
|
|
| Recruiting | N/A | 90 | US | Cognitive Behavioral Therapy for Nightmares in Children | University of Oklahoma, University of Tulsa | Nightmare, Suicidal Ideation, Children, Only | 01/26 | 01/26 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Book, Linda |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia, Neonatal Cholestasis | 05/29 | 05/29 | | |
| Recruiting | N/A | 1265 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Biliary Atresia | 05/29 | 05/29 | | |
| Suspended | N/A | 1675 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency | 05/29 | 05/29 | | |
| Suspended | N/A | 67 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Michigan | Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation | 05/29 | 05/29 | | |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing | 05/29 | 05/29 | | |
NCT03115086: The REPLACE Registry for Cholbam® (Cholic Acid) |
|
|
| Active, not recruiting | N/A | 55 | US | Cholbam | Mirum Pharmaceuticals, Inc. | Bile Acid Synthesis Disorders | 07/38 | 07/39 | | |
| Nichols, Amy |
| Recruiting | 3 | 198 | US | GIE Medical ProTractX3 TTS DCB, Control | GIE Medical | Esophageal Stricture | 07/25 | 12/29 | | |
| Recruiting | 3 | 171 | US | GIE Medical ProTractX3 TTS DCB, Control | GIE Medical | Bowel; Stricture | 09/24 | 03/29 | | |
| Recruiting | 2 | 75 | Europe, Canada, US, RoW | barzolvolimab, Matching Placebo | Celldex Therapeutics, Celldex Therapeutics, Inc. | Eosinophilic Esophagitis | 03/25 | 08/25 | | |
NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months |
|
|
| Recruiting | 1c | 63 | US | Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose) | Meissa Vaccines, Inc. | Respiratory Syncytial Virus (RSV) | 10/23 | 10/23 | | |
| Recruiting | N/A | 30 | US | | Children's Hospital Medical Center, Cincinnati | Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder | 05/25 | 06/25 | | |
| Rosen, Priscilla |
| Recruiting | 1/2 | 34 | Europe, Japan, US, RoW | Asciminib Pediatric formulation group, ABL001, Asciminib Adult formulation group | Novartis Pharmaceuticals, Novartis Pharma AG | Myeloid Leukemia, Philadelphia Positive | 06/26 | 11/31 | | |
| PI, Brian Mickey |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
| Burton, Vera Joanna |
| Recruiting | N/A | 267 | US | APPLES-tele, C-Mitt, Parent-centered Approach (PCA) Support Intervention, Standard of Care | Emory University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Cerebral Palsy | 08/26 | 02/27 | | |
| Ostrander, Betsy |
| Recruiting | N/A | 267 | US | APPLES-tele, C-Mitt, Parent-centered Approach (PCA) Support Intervention, Standard of Care | Emory University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Cerebral Palsy | 08/26 | 02/27 | | |
| Reyes, Leonel |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Active, not recruiting | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 02/25 | | |
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA |
|
|
| Terminated | 3 | 196 | US | TC99m-tilmanocept, tilmanocept, Lymphoseek | Navidea Biopharmaceuticals | Rheumatoid Arthritis | 07/24 | 07/24 | | |
NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/25 | 03/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension |
|
|
| Enrolling by invitation | 3 | 1400 | Europe, Canada, US, RoW | lorundrostat, Placebo | Mineralys Therapeutics Inc. | Hypertension | 12/25 | 12/26 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
| Deneau, Mark |
| Recruiting | N/A | 1000 | Canada, US | | Arbor Research Collaborative for Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing | 05/29 | 05/29 | | |
| Zahabi, Fehmida |
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension |
|
|
| Enrolling by invitation | 3 | 1400 | Europe, Canada, US, RoW | lorundrostat, Placebo | Mineralys Therapeutics Inc. | Hypertension | 12/25 | 12/26 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
| Chaudhari, Bimal |
NCT06046820: The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency |
|
|
| Recruiting | 3 | 33 | Europe, Canada, US, RoW | INZ-701, (rhENPP1-Fc)., Control Arm (Conventional Therapy) | Inozyme Pharma | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy | 05/25 | 06/25 | | |
ENERGY, NCT05734196: The Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency |
|
|
| Recruiting | 1 | 16 | Europe, US | INZ-701, (rhENPP1-Fc). | Inozyme Pharma | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum | 03/26 | 04/26 | | |
| Kraus, Kellie |
| Recruiting | 3 | 2060 | Europe, Canada, Japan, US, RoW | Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen | Novartis Pharmaceuticals | Relapsing Multiple Sclerosis | 12/27 | 09/28 | | |
|
| Gordon, Dempsey |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
